Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | +0.45% | -0.22% | -12.65% |
Business Summary
Number of employees: 37
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Central Nervous System Therapies
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 31/12/99 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 20/08/23 |
Joshua Prince
COO | Chief Operating Officer | 54 | 31/10/21 |
Ross Baker
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/21 |
Ann Cunningham
BRD | Director/Board Member | 56 | 09/01/19 |
Mark McPartland
IRC | Investor Relations Contact | 58 | 03/10/16 |
Jessica Haskell
SEC | Corporate Secretary | - | 31/07/22 |
Human Resources Officer | - | 31/12/21 | |
Erik Berglund
LAW | General Counsel | - | 31/01/21 |
Louis Monti
PRN | Corporate Officer/Principal | - | 30/11/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 31/05/00 |
Jerry Gin
BRD | Director/Board Member | 81 | 29/02/16 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 31/12/99 |
Chairman | 58 | 20/07/21 | |
Ann Cunningham
BRD | Director/Board Member | 56 | 09/01/19 |
Joanne Curley
BRD | Director/Board Member | 56 | 22/04/21 |
Mary Rotunno
BRD | Director/Board Member | 64 | 05/07/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,029,731 | 26,971,854 ( 99.79 %) | 4,522 ( 0.0167 %) | 99.79 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.65% | 121M | |
+2.78% | 108B | |
+10.25% | 104B | |
+2.42% | 22.33B | |
-11.94% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-8.89% | 17.64B | |
+6.52% | 14.05B | |
+35.94% | 12.51B |
- Stock Market
- Equities
- VTGN Stock
- Company Vistagen Therapeutics, Inc.